country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-181558

Copy Link Print Information

Anticancer agent 303

Anticancer agent 303 is a selective, orally active anticancer agent belonging to the pyrazolopyridine derivatives. Anticancer agent 303 exhibits low cytotoxicity to healthy cells, with a selective window of approximately 2-fold between cancer cells and healthy cells. Anticancer agent 303 produces detectable systemic exposure in mice following intraperitoneal or oral administration. Anticancer agent 303 effectively inhibits the proliferation of prostate cancer and breast cancer cells.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

分子式: C₂₇H₃₀N₆O₂
分子量:470.57

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (274 KB)

Anticancer agent 303 構造式

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- 体外実験
- Parmacokinetics
- 体内実験
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

体外実験

Anticancer agent 303 (compound 17) (5 μM; 72 h) inhibits the viability of PC-3, MCF-7 and HUVEC cells, with mean IC₅₀ values of 4.8 μM, 3.9 μM and 8.7 μM, respectively^[1].
Anticancer agent 303 (5 μM; 1-24 h) accumulates in PC-3 cells in a time-dependent manner, reaching a level of 245.8 ng/40,000 cells (104.5% of the initial administered dose) after 24 h of treatment at 5 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

human prostate adenocarcinoma PC-3 cells
Concentration:

5 μM
Incubation Time:

72 h
Result:

Reduced PC-3 cell viability to 36% relative to DMSO control.
Exhibited an average IC₅₀ of 4.8 ± 0.9 μM.

Cell Cytotoxicity Assay^[1]

Cell Line:

human breast adenocarcinoma MCF-7 cells
Concentration:

5 μM
Incubation Time:

72 h
Result:

Reduced MCF-7 cell viability to 33% relative to DMSO control.
Exhibited an average IC₅₀ of 3.9 ± 0.9 μM.

Parmacokinetics

Species	Dose	Route	C_max	T_max	T_1/2	AUC_0-t	AUC_0-∞	Bioavailability
Mice^[1]	4 mg/kg	i.p.	372.2 ng/mL	4.8 h	14.4 h	5847.1 ng·h/mL	8721.3 ng·h/mL	/
Mice^[1]	8 mg/kg	p.o.	199.0 ng/mL	6.5 h	16.3 h	3338.0 ng·h/mL	5299.1 ng·h/mL	29.13 %

体内実験

Anticancer agent 303 (compound 17) achieves systemic exposure in mice via intraperitoneal (i.p.) and oral (p.o.) administration. Intraperitoneal injection yields higher systemic exposure than oral administration, as indicated by increased Cmax and AUC, and has a shorter time to peak concentration (Tmax), while the elimination half-lives of the two administration routes are similar. In addition, the dose-normalized relative oral bioavailability of Anticancer agent 303 is 29.13%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

分子量 470.57
分子式 C₂₇H₃₀N₆O₂
SMILES

O=C(NC1=CC=CC=C1)NC2=CC(OCCNC3CCCCC3)=C4C(N(C5=CC=CC=C5)N=C4)=N2
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (274 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Georgiou M, et al. Optimization of Pyrazolo[3,4‑b]pyridine Analogues: Synthesis, In Vitro Anticancer Evaluation and In Vivo Pharmacokinetics. ACS Omega. 2026;11(5):8479-8495. Published 2026 Jan 24. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ